Impact of BNT162b2 primary vaccination and homologous booster on anti-SARS-CoV-2 IgA antibodies in baseline seronegative healthcare workers

Salvagno Gian Luca; Henry Brandon M.; Pighi Laura; De Nitto Simone; Lippi Giuseppe

doi:10.1515/almed-2022-0033

Advances in Laboratory Medicine (May 2022)

Impact of BNT162b2 primary vaccination and homologous booster on anti-SARS-CoV-2 IgA antibodies in baseline seronegative healthcare workers

Salvagno Gian Luca,
Henry Brandon M.,
Pighi Laura,
De Nitto Simone,
Lippi Giuseppe

Affiliations

Salvagno Gian Luca: Section of Clinical Biochemistry, University of Verona, Verona, Italy
Henry Brandon M.: Clinical Laboratory, Division of Nephrology and Hypertension, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA
Pighi Laura: Section of Clinical Biochemistry, University of Verona, Verona, Italy
De Nitto Simone: Section of Clinical Biochemistry, University of Verona, Verona, Italy
Lippi Giuseppe: Section of Clinical Biochemistry, University of Verona, Verona, Italy

DOI: https://doi.org/10.1515/almed-2022-0033
Journal volume & issue: Vol. 3, no. 2
pp. 167 – 170

Abstract

Read online

We investigated here the response of anti-SARS-CoV-2 IgA antibodies to BNT162b2 primary vaccination followed by administration of a homologous booster dose in baseline seronegative healthcare workers.

Published in Advances in Laboratory Medicine

ISSN: 2628-491X (Online)
Publisher: De Gruyter
Country of publisher: Germany
LCC subjects: Medicine: Medicine (General): Medical technology
Website: https://www.degruyter.com/journal/key/almed/html

About the journal

Abstract

Keywords